Banca de QUALIFICAÇÃO: LARA EMILY OLIVEIRA SOUSA

Uma banca de QUALIFICAÇÃO de MESTRADO foi cadastrada pelo programa.
STUDENT : LARA EMILY OLIVEIRA SOUSA
DATE: 02/12/2025
TIME: 15:00
LOCAL: Sala II - Departamento de Odontologia
TITLE:

CLINICAL MANAGEMENT OF BENIGN ORAL VASCULAR ANOMALIES: A RETROSPECTIVE STUDY

KEY WORDS:

hemangiomas, vascular malformations, oral cavity, sclerotherapy, oral surgery.

PAGES: 64
BIG AREA: Ciências da Saúde
AREA: Odontologia
SUMMARY:

Introduction: Benign vascular anomalies are lesions that affect different parts of the body, most frequently the head and neck region, particularly the oral cavity. Treatment for these conditions can be classified as non-invasive, minimally invasive, or invasive, depending on lesion severity, location, and other associated factors. In this context, the absence of a standardized protocol for the clinical management of oral benign vascular anomalies (OBVAs) makes treatment challenging, increasing the risk of adverse effects and the use of inadequate therapeutic approaches. Objective: To conduct a retrospective study on the management and clinical outcomes of OBVAs diagnosed at the Stomatology Service of the Federal University of Rio Grande do Norte (UFRN). Materials and Methods: This retrospective, descriptive, and cross-sectional will be based on the review of clinical records of patients diagnosed with OBVAs and treated at the UFRN Stomatology Service between January 2020 and December 2025. The sample will be non-probabilistic and intentional, including only cases with a clinical diagnosis established according to the criteria of the International Society for the Study of Vascular Anomalies (ISSVA). Clinical and demographic data will be collected, including sex, age, race, comorbidities, and medication use. The clinical characteristics of OBVAs will include information on the type of fundamental lesion, duration, location, color, consistency, symptoms, secondary signs, growth pattern, implantation, size (mm), and clinical diagnosis. The treatment modalities employed (sclerotherapy, surgery, clinical follow-up, or other) will be recorded. For cases treated with sclerotherapy, information on the sclerosing agent, concentration, dose, number and interval of sessions, as well as adverse effects and therapeutic measures adopted to minimize them, will be collected. Finally, lesion recurrence and the final clinical outcome, classified as complete regression, partial regression, or no regression, will be assessed. Statistical analysis will be performed using Pearson’s chi-square test and Fisher’s exact test to identify associations between variables, considering a significance level of 5% (p < 0.05).

COMMITTEE MEMBERS:
Interna - 3218128 - AMANDA KATARINNY GOES GONZAGA
Interno - ***.957.264-** - CIRO DANTAS SOARES - UnP
Interna - 1258693 - LELIA MARIA GUEDES QUEIROZ